Home NDC 61958-1201 Stribild
Product NDC 61958-1201
11-digit product format 619581201
Labeler code 61958
Product ID 61958-1201_65c2d2eb-d180-41c3-b346-9cdc6e52d5ed
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate
Dosage form TABLET, FILM COATED
Route ORAL
Labeler Gilead Sciences, Inc.
Application NDA203100
Marketing category NDA
Marketing start 2012-08-27
Substance COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
Active strength 150; 150; 200; 300 mg/1; mg/1; mg/1; mg/1
Pharmacologic classes Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A Inhibitor [EPC], Cytochrome P450 3A Inhibitors [MoA], HIV Integrase Inhibitors [MoA], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], Nucleoside Reverse Transcriptase Inhibitors [MoA], Nucleoside Reverse Transcriptase Inhibitors [MoA], Nucleosides [CS], Nucleosides [CS], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA]
NDC exclude flag No
Listing certified through 2026-12-31
Current FDA listing Yes Observed NDC auxiliary status history# This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.
Historic NDC status page 1 of 1 · 6 matching rows.
View current auxiliary records. · View the auxiliary file history.
Captured / source date, Dataset, Scope table Captured / source date Dataset Scope Package NDC Snapshot Source SHA-256 2025-02-02 03:52 UTC · source 2025-01-31 excluded product product 302b2466d912…e7b80fea0513…2025-02-02 03:52 UTC · source 2025-01-31 excluded package package 61958-1201-1 302b2466d912…e7b80fea0513…2025-01-20 13:05 UTC · source 2025-01-20 excluded product product ed331223b511…672a5bd82f5f…2025-01-20 13:05 UTC · source 2025-01-20 excluded package package 61958-1201-1 ed331223b511…672a5bd82f5f…2025-01-11 03:41 UTC · source 2025-01-10 excluded product product 0efc9e666f02…f202fb6c5f17…2025-01-11 03:41 UTC · source 2025-01-10 excluded package package 61958-1201-1 0efc9e666f02…f202fb6c5f17…
Source provenance: Browse the complete Orange Book source catalog · source snapshot 1 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N203100-001 STRIBILD COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27
Orange Book patents# Current patent rows page 1 of 1 · 14 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N203100-001 7176220 2026-08-27 U-257 Drug substance, Drug product N203100-001 7635704 2026-10-26 U-257 Drug substance, Drug product N203100-001 8981103 2026-10-26 Drug substance, Drug product 2015-04-14 N203100-001 7176220*PED 2027-02-27 Pediatric extension N203100-001 7635704*PED 2027-04-26 Pediatric extension N203100-001 8981103*PED 2027-04-26 Pediatric extension N203100-001 8148374 2029-09-03 U-1279 Drug substance, Drug product N203100-001 9891239 2029-09-03 U-257 Drug product 2018-03-06 N203100-001 8148374*PED 2030-03-03 Pediatric extension N203100-001 9891239*PED 2030-03-03 Pediatric extension N203100-001 8633219 2030-04-30 U-257 Drug product 2014-01-24 N203100-001 8633219*PED 2030-10-30 Pediatric extension N203100-001 10039718 2032-10-06 Drug product 2018-09-04 N203100-001 10039718*PED 2033-04-06 Pediatric extension
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 1 of 2 · 41 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-02-19 14:30 UTC 2026-02 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 2680178bc6a6…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 5bbf6a4d5a75…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 d8e5a09893c0…2024-10-29 15:01 UTC 2024-10 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 d06236e962d9…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 79d66fd596c7…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 301d65b070ca…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 1e350fbaab3a…2024-05-31 18:47 UTC 2024-05 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 8072bd15b7f6…2022-06-29 02:47 UTC · 2 captures of this ZIP 2022-06 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 5c6f7cd8ea54…2022-04-08 23:34 UTC 2022-04 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 5d02ea3f76ae…2022-04-04 05:41 UTC 2022-04 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 4b0b4de00fa7…2019-12-13 00:20 UTC 2019-12 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 74a2ff9319b5…2022-03-09 01:35 UTC 2022-03 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 bb7c543d1eb4…2021-12-28 21:50 UTC 2021-12 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 782e0a99824c…2021-05-05 16:15 UTC · 3 captures of this ZIP 2021-05 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 87673890dc5c…2021-03-12 10:30 UTC 2021-03 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 5aa47cf7b7d7…2020-12-22 03:56 UTC 2020-12 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 8869cabd3fbd…2020-11-12 02:37 UTC 2020-11 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 c0c555d07b60…2019-12-14 00:12 UTC 2019-12 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 3f01610625f2…2019-09-15 20:21 UTC 2019-09 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 b00525d2431f…2019-07-19 19:46 UTC 2019-07 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 ea99ee380514…2024-03-16 18:09 UTC · 4 captures of this ZIP 2024-03 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 6a51e52b5d6a…2024-02-18 07:12 UTC 2024-02 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 1c564ffb4f44…2023-12-20 04:57 UTC 2023-12 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 ea1830bbd6c7…2023-11-28 05:40 UTC · 2 captures of this ZIP 2023-11 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 a72a2bbeb626…2023-10-25 00:34 UTC · 2 captures of this ZIP 2023-10 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 9b2671bbb829…2023-07-15 15:27 UTC · 2 captures of this ZIP 2023-07 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 a67488948f0b…2023-06-13 01:57 UTC · 3 captures of this ZIP 2023-06 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 3f0d92c62455…2023-05-13 08:27 UTC 2023-05 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 053a50430f4f…2023-01-26 05:58 UTC 2023-01 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 3bdfa0b2c4d7…2022-11-12 20:34 UTC · 5 captures of this ZIP 2022-11 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 3a93d1ddd44b…2022-10-28 04:53 UTC 2022-10 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 f41ea6bd6efb…2022-09-29 23:25 UTC 2022-09 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 e64feba35796…2022-07-09 03:26 UTC · 3 captures of this ZIP 2022-07 N203100-001 STRIBILD 150MG;150MG;200MG;300MG TABLET / ORAL RLD, RS 2012-08-27 cb3db0bc1861…
Observed Orange Book patent history# Patent history page 1 of 18 · 691 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-02-19 14:30 UTC 2026-02 N203100-001 7176220 2026-08-27 U-257 Drug substance, Drug product 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N203100-001 7635704 2026-10-26 U-257 Drug substance, Drug product 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N203100-001 8981103 2026-10-26 Drug substance, Drug product 2015-04-14 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N203100-001 7176220*PED 2027-02-27 Pediatric extension 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N203100-001 7635704*PED 2027-04-26 Pediatric extension 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N203100-001 8981103*PED 2027-04-26 Pediatric extension 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N203100-001 8148374 2029-09-03 U-1279 Drug substance, Drug product 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N203100-001 9891239 2029-09-03 U-257 Drug product 2018-03-06 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N203100-001 8148374*PED 2030-03-03 Pediatric extension 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N203100-001 9891239*PED 2030-03-03 Pediatric extension 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N203100-001 8633219 2030-04-30 U-257 Drug product 2014-01-24 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N203100-001 8633219*PED 2030-10-30 Pediatric extension 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N203100-001 10039718 2032-10-06 Drug product 2018-09-04 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N203100-001 10039718*PED 2033-04-06 Pediatric extension 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N203100-001 7176220 2026-08-27 U-257 Drug substance, Drug product 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N203100-001 7635704 2026-10-26 U-257 Drug substance, Drug product 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N203100-001 8981103 2026-10-26 Drug substance, Drug product 2015-04-14 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N203100-001 7176220*PED 2027-02-27 Pediatric extension 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N203100-001 7635704*PED 2027-04-26 Pediatric extension 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N203100-001 8981103*PED 2027-04-26 Pediatric extension 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N203100-001 8148374 2029-09-03 U-1279 Drug substance, Drug product 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N203100-001 9891239 2029-09-03 U-257 Drug product 2018-03-06 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N203100-001 8148374*PED 2030-03-03 Pediatric extension 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N203100-001 9891239*PED 2030-03-03 Pediatric extension 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N203100-001 8633219 2030-04-30 U-257 Drug product 2014-01-24 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N203100-001 8633219*PED 2030-10-30 Pediatric extension 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N203100-001 10039718 2032-10-06 Drug product 2018-09-04 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N203100-001 10039718*PED 2033-04-06 Pediatric extension 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N203100-001 7176220 2026-08-27 U-257 Drug substance, Drug product 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N203100-001 7635704 2026-10-26 U-257 Drug substance, Drug product 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N203100-001 8981103 2026-10-26 Drug substance, Drug product 2015-04-14 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N203100-001 7176220*PED 2027-02-27 Pediatric extension 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N203100-001 7635704*PED 2027-04-26 Pediatric extension 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N203100-001 8981103*PED 2027-04-26 Pediatric extension 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N203100-001 8148374 2029-09-03 U-1279 Drug substance, Drug product 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N203100-001 9891239 2029-09-03 U-257 Drug product 2018-03-06 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N203100-001 8148374*PED 2030-03-03 Pediatric extension 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N203100-001 9891239*PED 2030-03-03 Pediatric extension 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N203100-001 8633219 2030-04-30 U-257 Drug product 2014-01-24 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N203100-001 8633219*PED 2030-10-30 Pediatric extension 6a471c1ec25d…
Observed Orange Book exclusivity history# Additional Listing Data#
Finished product Yes
Brand name base Stribild
Listing expiration 2026-12-31 Active Ingredients# Ingredient, Strength table Ingredient Strength ELVITEGRAVIR 150 mg/1 COBICISTAT 150 mg/1 EMTRICITABINE 200 mg/1 TENOFOVIR DISOPROXIL FUMARATE 300 mg/1
Harmonized UNII identifiers# UNII identifiers page 1 of 1 · 4 matching rows.
Harmonized RxCUI identifiers# RxCUI identifiers page 1 of 1 · 2 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination 1306292 Internal RxNorm lookup 1306298 Internal RxNorm lookup
Harmonized SPL set identifiers# SPL set identifiers page 1 of 1 · 1 matching rows.
DailyMed Product Concepts# FDA-Initiated Inactive NDC Indexing# NDC, Effective, Action table NDC Effective Action Document Indexing SPL Related label 61958-1201-1 2025-02-12 C162847 48780-1 ab0e2407-3349-f274-e053-dbdaa90a6471 These highlights do not include all the information needed to use STRIBILD safely and effectively. See full prescribing information for STRIBILD. STRIBILD ® (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) tablets, for oral use Initial U.S. Approval: 2012 61958-1201-1 2025-01-30 C162847 48780-1 ab0e2407-3349-f274-e053-dbdaa90a6471 These highlights do not include all the information needed to use STRIBILD safely and effectively. See full prescribing information for STRIBILD. STRIBILD ® (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) tablets, for oral use Initial U.S. Approval: 2012 61958-1201-1 2020-07-22 C162847 48780-1 ab0e2407-3349-f274-e053-dbdaa90a6471 These highlights do not include all the information needed to use STRIBILD safely and effectively. See full prescribing information for STRIBILD. STRIBILD ® (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) tablets, for oral use Initial U.S. Approval: 2012
DailyMed Package Descriptions# Package NDC, Product, Description table Package NDC Product Description Form Quantity Strength SPL version 61958-1201-1 Stribild 30 in 1 BOTTLE, PLASTIC TABLET, FILM COATED 30 22
DailyMed Socrata Ingredients# Ingredient, Type, UNII table Ingredient Type UNII DailyMed label SPL version Uploaded cobicistat ACTIVE INGREDIENT LW2E03M5PG STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [GILEAD SCIENCES, INC.] 7 elvitegravir ACTIVE INGREDIENT 4GDQ854U53 STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [GILEAD SCIENCES, INC.] 7 emtricitabine ACTIVE INGREDIENT G70B4ETF4S STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [GILEAD SCIENCES, INC.] 7 tenofovir disoproxil fumarate ACTIVE INGREDIENT OTT9J7900I STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [GILEAD SCIENCES, INC.] 7 cobicistat ACTIVE MOIETY LW2E03M5PG STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [GILEAD SCIENCES, INC.] 7 elvitegravir ACTIVE MOIETY 4GDQ854U53 STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [GILEAD SCIENCES, INC.] 7 emtricitabine ACTIVE MOIETY G70B4ETF4S STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [GILEAD SCIENCES, INC.] 7 TENOFOVIR ANHYDROUS ACTIVE MOIETY W4HFE001U5 STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [GILEAD SCIENCES, INC.] 7 ALUMINUM OXIDE INACTIVE INGREDIENT LMI26O6933 STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [GILEAD SCIENCES, INC.] 7 CELLULOSE, MICROCRYSTALLINE INACTIVE INGREDIENT OP1R32D61U STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [GILEAD SCIENCES, INC.] 7 CROSCARMELLOSE SODIUM INACTIVE INGREDIENT M28OL1HH48 STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [GILEAD SCIENCES, INC.] 7 FD&C BLUE NO. 2 INACTIVE INGREDIENT L06K8R7DQK STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [GILEAD SCIENCES, INC.] 7 FERRIC OXIDE YELLOW INACTIVE INGREDIENT EX438O2MRT STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [GILEAD SCIENCES, INC.] 7 HYDROXYPROPYL CELLULOSE (TYPE H) INACTIVE INGREDIENT RFW2ET671P STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [GILEAD SCIENCES, INC.] 7 LACTOSE MONOHYDRATE INACTIVE INGREDIENT EWQ57Q8I5X STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [GILEAD SCIENCES, INC.] 7 MAGNESIUM STEARATE INACTIVE INGREDIENT 70097M6I30 STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [GILEAD SCIENCES, INC.] 7 POLYETHYLENE GLYCOL 3350 INACTIVE INGREDIENT G2M7P15E5P STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [GILEAD SCIENCES, INC.] 7 POLYVINYL ALCOHOL INACTIVE INGREDIENT 532B59J990 STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [GILEAD SCIENCES, INC.] 7 SILICON DIOXIDE INACTIVE INGREDIENT ETJ7Z6XBU4 STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [GILEAD SCIENCES, INC.] 7 SODIUM LAURYL SULFATE INACTIVE INGREDIENT 368GB5141J STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [GILEAD SCIENCES, INC.] 7 TALC INACTIVE INGREDIENT 7SEV7J4R1U STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [GILEAD SCIENCES, INC.] 7 TITANIUM DIOXIDE INACTIVE INGREDIENT 15FIX9V2JP STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [GILEAD SCIENCES, INC.] 7 COBICISTAT ACTIVE INGREDIENT LW2E03M5PG STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [STATE OF FLORIDA DOH CENTRAL PHARMACY] 1 ELVITEGRAVIR ACTIVE INGREDIENT 4GDQ854U53 STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [STATE OF FLORIDA DOH CENTRAL PHARMACY] 1 EMTRICITABINE ACTIVE INGREDIENT G70B4ETF4S STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [STATE OF FLORIDA DOH CENTRAL PHARMACY] 1 TENOFOVIR DISOPROXIL FUMARATE ACTIVE INGREDIENT OTT9J7900I STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [STATE OF FLORIDA DOH CENTRAL PHARMACY] 1 COBICISTAT ACTIVE MOIETY LW2E03M5PG STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [STATE OF FLORIDA DOH CENTRAL PHARMACY] 1 ELVITEGRAVIR ACTIVE MOIETY 4GDQ854U53 STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [STATE OF FLORIDA DOH CENTRAL PHARMACY] 1 EMTRICITABINE ACTIVE MOIETY G70B4ETF4S STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [STATE OF FLORIDA DOH CENTRAL PHARMACY] 1 TENOFOVIR ANHYDROUS ACTIVE MOIETY W4HFE001U5 STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [STATE OF FLORIDA DOH CENTRAL PHARMACY] 1 ALUMINUM OXIDE INACTIVE INGREDIENT LMI26O6933 STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [STATE OF FLORIDA DOH CENTRAL PHARMACY] 1 CELLULOSE, MICROCRYSTALLINE INACTIVE INGREDIENT OP1R32D61U STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [STATE OF FLORIDA DOH CENTRAL PHARMACY] 1 COLLOIDAL SILICON DIOXIDE INACTIVE INGREDIENT ETJ7Z6XBU4 STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [STATE OF FLORIDA DOH CENTRAL PHARMACY] 1 CROSCARMELLOSE SODIUM INACTIVE INGREDIENT M28OL1HH48 STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [STATE OF FLORIDA DOH CENTRAL PHARMACY] 1 FD&C BLUE NO. 2 INACTIVE INGREDIENT L06K8R7DQK STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [STATE OF FLORIDA DOH CENTRAL PHARMACY] 1 FERRIC OXIDE YELLOW INACTIVE INGREDIENT EX438O2MRT STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [STATE OF FLORIDA DOH CENTRAL PHARMACY] 1 HYDROXYPROPYL CELLULOSE (TYPE H) INACTIVE INGREDIENT RFW2ET671P STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [STATE OF FLORIDA DOH CENTRAL PHARMACY] 1 LACTOSE MONOHYDRATE INACTIVE INGREDIENT EWQ57Q8I5X STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [STATE OF FLORIDA DOH CENTRAL PHARMACY] 1 MAGNESIUM STEARATE INACTIVE INGREDIENT 70097M6I30 STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [STATE OF FLORIDA DOH CENTRAL PHARMACY] 1 POLYETHYLENE GLYCOL 3350 INACTIVE INGREDIENT G2M7P15E5P STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [STATE OF FLORIDA DOH CENTRAL PHARMACY] 1 POLYVINYL ALCOHOL INACTIVE INGREDIENT 532B59J990 STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [STATE OF FLORIDA DOH CENTRAL PHARMACY] 1 SODIUM LAURYL SULFATE INACTIVE INGREDIENT 368GB5141J STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [STATE OF FLORIDA DOH CENTRAL PHARMACY] 1 TALC INACTIVE INGREDIENT 7SEV7J4R1U STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [STATE OF FLORIDA DOH CENTRAL PHARMACY] 1 TITANIUM DIOXIDE INACTIVE INGREDIENT 15FIX9V2JP STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [STATE OF FLORIDA DOH CENTRAL PHARMACY] 1
DailyMed Dashboard NDC Coverage# NDC, Dashboard title, SPL version table NDC Dashboard title SPL version Validation Dashboard ZIP 61958-1201 STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [GILEAD SCIENCES, INC.] 22 Current NDC, Legacy NDC, 1 package rows 20250214_74ae2a93-b267-444c-8f0f-a2a6522260ee.zip
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
Brand, Generic, Manufacturer table Brand Generic Manufacturer SPL set ID Effective date Available safety fields Join Stribild ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE Gilead Sciences, Inc. 74ae2a93-b267-444c-8f0f-a2a6522260ee 2025-02-04 Boxed warning, Warnings, Adverse reactions Exact identifier application applno (NDA): 203100 application number: NDA203100 ndc (product): 61958-1201
DailyMed RxNorm Mappings# Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Marketing start Marketing end Sample Exclude flag Status 61958-1201-1 61958120101 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61958-1201-1) 2012-08-27 0000-00-00 No No Current